By Charlie Lewis, AcceleDev’s Managing Director. As we find ourselves in the midst of February 2024, I am filled with a profound sense of gratitude, hope, and optimism. This sentiment stems from our reflections on the past year—a year marked by both significant achievements and formidable challenges. The pharmaceutical industry’s landscape has undergone rapid transformation, and while the post-pandemic economy has presented hurdles, our collective journey has been one defined by resilience and growth.
In 2023, AcceleDev celebrated several milestones, including the launch of a cutting-edge commercial manufacturing facility and the expansion of our team with the addition of 15 experienced process bench chemists and management staff. These expansions, spanning across the United States and China, have bolstered our total multipurpose production capacity to 668m3 and increased our team of process chemists to 70. This enhanced capacity empowers us to effectively manage the growing number of API early development and production phase programs, further solidifying our position in the industry.
Despite the economic challenges that have impacted many within our sector, AcceleDev has remained steadfast in its commitment to growth and improvement. We take pride in our recent recognition as a recipient of EcoVadis’ Bronze Medal award for sustainability excellence—an acknowledgment of our dedication to responsible and sustainable business practices.
Looking ahead, we are excited to announce our planned expansions in research and development (R&D) and quality at our U.S. headquarters in New Jersey. This strategic move not only signifies our commitment to growth but also serves as a testament to our pledge to exceed your expectations. Your invaluable feedback continues to shape our expansion efforts and service offerings, ensuring that we remain aligned with your evolving needs and the demands of the industry at large. Your trust and partnership have been instrumental in our success, and as we navigate the complexities of our industry, we remain dedicated to growing alongside you.
On behalf of the entire AcceleDev team, I extend our sincerest gratitude for your unwavering support and partnership. Together, we eagerly anticipate reaching new heights and making a meaningful impact in the pharmaceutical landscape in 2024 and beyond.